AbbVie, an international biopharmaceutical company, has just opened the window for application to those interested in this year’s AbbVie CF Scholarship – exclusively available to students afflicted with cystic fibrosis (CF). The company started accepting applications yesterday, and will be doing so until Monday, June 9. Those interested can visit www.AbbVieCFScholarship.com to learn more.
The scholarship will be granted to creative students who have excelled in their academics, are active in the community, and can act as a constructive role model to others with CF. This year, to commemorate the scholarship’s 22nd year, 40 of its beneficiaries will be given a golden opportunity to earn a Thriving Student Scholarship and win $22,000.
MRSA is a serious threat to CF patients. Get more information about [adrotate banner=”75″].
According to the vice president of AbbVie’s Endocrinology, Metabolic, GI Care and Institutional Accounts, Jim Hynd, the company is extremely proud to be a catalyst in molding students with CF to excel and be seen as inspirations.
Cystic fibrosis is a genetic, lifelong disorder that causes the body to secrete copious, thick mucus that can impede respiratory structures, causing ineffective breathing and potentially life threatening infections. The viscous secretions can also block pancreatic enzymes from aiding in proper digestion, leading to malabsorption. In the US, about 30,000 people suffer from CF, and it is expected that every year, 1,000 new CF diagnoses are made.
The disease also remains a popular and widely supported patient population nationwide, with a strong and growing network of celebrities, philanthropists, and other advocates working with drug developers and hospitals to further advance therapies and care for those with CF. Last week, BioNews Texas profiled a recent Cystic Fibrosis online fundraising effort from company FiltersFast.com in order to raise money to accelerate both research and an eventual cure. With small and large companies alike investing in the future of cystic fibrosis patients, the prospect of effective treatments over the next few years is indeed a reality.